Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029668 | 0.95 | LMNA (0.52) | LMNAL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL1034033 | 0.86 | LMNA (0.74) | LMNAL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL637767 | 0.85 | HTT (0.58) | LMNAL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL2490841 | 0.85 | LMNA (0.63) | LMNAL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL12421826 | 0.84 | LMNA (0.72) | LMNAL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL3173616 | 0.84 | LMNA (0.48) | LMNAL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL12313922 | 0.84 | LMNA (0.44) | LMNAL3MBTL1GAAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11741238 | 0.83 | LMNA (0.70) | LMNAL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL31087496 | 0.83 | LMNA (0.42) | LMNAL3MBTL1GAAMEN1KMT2A | |
| SCHEMBL13295566 | 0.80 | CYP1A2 (0.52) | LMNAGAAMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-8263385-B2 | S-triazine-herbicide-degrading bacteria, product for the bioremediation and method of bioremediation | Universidad Technica Fedrico Santa Maria (CL) | 2012-09-11 | — | — | US | claimed |
| US-20090017525-A1 | S-TRIAZINE-HERBICIDE-DEGRADING BACTERIA, PRODUCT FOR THE BIOREMEDIATION AND METHOD OF BIOREMEDIATION | UNIVERSIDAD TECNICA FEDERICO SANTA MARIA (CL) | 2009-01-15 | — | — | US | claimed |
| EP-0365818-B1 | Immunological detection of atrazine and atrazine derivatives | CIBA GEIGY AG (CH) | 1995-02-15 | — | — | EP | claimed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| US-7208018-B2 | Composition for dyeing human keratin materials, comprising at least one fluorescent dye and at least one associative polymer, process therefor and use thereof | L'OREAL (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7204860-B2 | Composition for dyeing human keratin materials, comprising at least one fluorescent dye and at least one polyol, process therefor and use thereof | L'OREAL (FR) | 2007-04-17 | — | — | US | disclosed |
| US-7201779-B2 | Dye composition comprising at least one direct dye containing mixed chromophores | L'OREAL S.A. (FR) | 2007-04-10 | — | — | US | disclosed |
| US-7198650-B2 | Method of dyeing human keratin materials with a lightening effect with compositions comprising at least one fluorescent dye and at least one amphoteric or nonionic surfactant, composition thereof, process thereof, and device therefor | L'OREAL S.A. (FR) | 2007-04-03 | — | — | US | disclosed |
| US-7195651-B2 | Cosmetic composition for dyeing human keratin materials, comprising at least one fluorescent dye and at least one cationic polymer, and a dyeing process therefor | L'OREAL S.A. (FR) | 2007-03-27 | — | — | US | disclosed |
| US-7195650-B2 | Process for dyeing, with a lightening effect, human keratin fibers that have been permanently reshaped, using at least one composition comprising at least one fluorescent dye | L'OREAL S.A. (FR) | 2007-03-27 | — | — | US | disclosed |
| US-7186278-B2 | Composition for dyeing human keratin materials, comprising at least one fluorescent dye and at least one compound comprising an acid functional group and processes therefor | L'OREAL S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
| US-7172633-B2 | Lightening dye composition comprising at least one cationic direct dye containing mixed chromophores | L'ORéAL S.A. (FR) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | LMNA 3363/4885L3MBTL1 1070/4885GAA 2124/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | LMNA 3363/4885L3MBTL1 1070/4885GAA 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.